Barclays initiated coverage of Cencora (COR) with an Overweight rating and $400 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora, Inc. Faces Business Risks from Unpredictable Global Events
- Cencora price target raised to $417 from $344 at JPMorgan
- Cencora price target raised to $405 from $354 at Wells Fargo
- Cencora price target raised to $400 from $350 at TD Cowen
- Cencora price target raised to $371 from $322 at Deutsche Bank